Biomarkers in localized prostate cancer

被引:41
|
作者
Ferro, Matteo [1 ]
Buonerba, Carlo [2 ]
Terracciano, Daniela [3 ]
Lucarelli, Giuseppe [4 ]
Cosimato, Vincenzo [3 ]
Bottero, Danilo [1 ]
Deliu, Victor M. [1 ]
Ditonno, Pasquale [4 ]
Perdona, Sisto [5 ]
Autorino, Riccardo [6 ]
Coman, Ioman [7 ]
De Placido, Sabino [2 ]
Di Lorenzo, Giuseppe [2 ]
De Cobelli, Ottavio [1 ,7 ]
机构
[1] European Inst Oncol, Div Oncol, Milan, Italy
[2] Univ Naples Federico II, Dept Clin Med & Surg, Med Oncol, Naples, Italy
[3] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy
[4] Univ Bari, Dept Emergency & Organ Transplantat Urol, Androl & Kidney Transplantat Unit, Bari, Italy
[5] Natl Canc Inst, Dept Urol, Naples, Italy
[6] Univ Hosp Case Med Ctr, Inst Urol, Cleveland, OH 44106 USA
[7] Univ Med & Pharm, Dept Urol Iuliu Hatieganu, Cluj Napoca 400012, Romania
关键词
biomarkers; prostate cancer; HEALTH INDEX PHI; ANTIGEN VELOCITY; ACTIVE SURVEILLANCE; KALLIKREIN MARKERS; SERUM SARCOSINE; BIOPSY RECLASSIFICATION; RADICAL PROSTATECTOMY; PROGNOSTIC VALUE; PRECURSOR FORM; RISK;
D O I
10.2217/fon.15.318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biomarkers can improve prostate cancer diagnosis and treatment. Accuracy of prostate-specific antigen (PSA) for early diagnosis of prostate cancer is not satisfactory, as it is an organ-but not cancer-specific biomarker, and it can be improved by using models that incorporate PSA along with other test results, such as prostate cancer antigen 3, the molecular forms of PSA (proPSA, benign PSA and intact PSA), as well as kallikreins. Recent reports suggest that new tools may be provided by metabolomic studies as shown by preliminary data on sarcosine. Additional molecular biomarkers have been identified by the use of genomics, proteomics and metabolomics. We review the most relevant biomarkers for early diagnosis and management of localized prostate cancer.
引用
收藏
页码:399 / 411
页数:13
相关论文
共 50 条
  • [1] Clinical Utility of Biomarkers in Localized Prostate Cancer
    Leapman, Michael S.
    Nguyen, Hao G.
    Cooperberg, Matthew R.
    [J]. CURRENT ONCOLOGY REPORTS, 2016, 18 (05)
  • [2] Clinical Utility of Biomarkers in Localized Prostate Cancer
    Michael S. Leapman
    Hao G. Nguyen
    Matthew R. Cooperberg
    [J]. Current Oncology Reports, 2016, 18
  • [3] Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
    Eggener, Scott E.
    Rumble, R. Bryan
    Armstrong, Andrew J.
    Morgan, Todd M.
    Crispino, Tony
    Cornford, Philip
    van der Kwast, Theodorus
    Grignon, David J.
    Rai, Alex J.
    Agarwal, Neeraj
    Klein, Eric A.
    Den, Robert B.
    Beltran, Himisha
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (13) : 1474 - +
  • [4] New biomarkers for diagnosis and prognosis of localized prostate cancer
    Chistiakov, Dimitry A.
    Myasoedova, Veronika A.
    Grechko, Andrey V.
    Melnichenko, Alexandra A.
    Orekhov, Alexander N.
    [J]. SEMINARS IN CANCER BIOLOGY, 2018, 52 : 9 - 16
  • [5] Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer
    Moul, Judd W.
    [J]. EUROPEAN UROLOGY FOCUS, 2022, 8 (03): : 641 - 642
  • [6] Molecular biomarkers to guide precision medicine in localized prostate cancer
    Smits, Minke
    Mehra, Niven
    Sedelaar, Michiel
    Gerritsen, Winald
    Schalken, Jack A.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (08) : 791 - 804
  • [7] Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy
    Hall, William A.
    Lawton, Colleen A.
    Jani, Ashesh B.
    Pollack, Alan
    Feng, Felix Y.
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (01) : 11 - 20
  • [8] Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary
    Eggener, Scott E.
    Rumble, R. Bryan
    Beltran, Himisha
    [J]. JCO ONCOLOGY PRACTICE, 2020, 16 (06) : 340 - +
  • [9] The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.
    Brastianos, Harry
    Murgic, Jure
    Salcedo, Adriana
    Chua, Melvin Lee Kiang
    Meng, Alice
    Fraser, Michael
    Brundage, Michael Donald
    Fleshner, Neil Eric
    van der Kwast, Theodorus
    Bristow, Robert G.
    Boutros, Paul Christopher
    Berlin, Alejandro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] DETERMINATION OF THE IMPACT OF INTRATUMOURAL HETEROGENEITY ON PROGNOSTIC BIOMARKERS IN LOCALIZED PROSTATE CANCER
    Brastianos, Harry
    Murgic, Jure
    Salcedo, Adriana
    Chua, Melvin
    Meng, Alice
    Fraser, Michael
    Brundage, Michael
    Fleshner, Neil
    van der Kwast, Theodorus
    Bristow, Robert
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S19 - S20